HAPP's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than merely 6.08% of US-listed equities with positive expected earnings growth.
Happiness Biotech Group Ltd's stock had its IPO on October 25, 2019, making it an older stock than just 0.69% of US equities in our set.
With a price/earnings ratio of 3.76, Happiness Biotech Group Ltd P/E ratio is greater than that of about merely 2.86% of stocks in our set with positive earnings.
If you're looking for stocks that are quantitatively similar to Happiness Biotech Group Ltd, a group of peers worth examining would be UG, BHAT, GIGM, JOUT, and SCON.
Happiness Biotech Group Ltd. is a nutraceutical and dietary supplements producer, which engages in the research, development, manufacturing, marketing, and sales of a variety of products made from herbal and animal extracts. The firm's products include lucidum spore powder; cordyceps mycelia; ijiao solution; and American ginseng. It operates under the brand name Happiness. The company was founded on February 9, 2018 and is headquartered in Nanping City, China.
HAPP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Happiness Biotech Group Ltd. To summarize, we found that Happiness Biotech Group Ltd ranked in the 29th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 55%. As for the metrics that stood out in our discounted cash flow analysis of Happiness Biotech Group Ltd, consider:
The company's compound free cash flow growth rate over the past 1.08 years comes in at -0.23%; that's greater than only 6.61% of US stocks we're applying DCF forecasting to.
The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than merely 14.08% of the free cash flow producing stocks we're observing.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
CDNA, JNJ, ZTS, HSIC, and IONS can be thought of as valuation peers to HAPP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Happiness Biotech ([[HAPP]] +15.5%) entered into a certain securities purchase agreement with three non-U.S. investors under which it has agreed to sell 900K ordinary shares at $2.5/share.Gross proceeds to be used for the development of Happy Buy's B2B e-Commerce business as well as for working capital and general corporate use."In addition to the capital,...
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company has declared a cash dividend of $0.015 per ordinary share, payable in cash on or about August 17, 2020, to shareholders of record on August 10, 2020.
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, today announced its financial results for the fiscal year ended March 31, 2020.
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the 75% Alcohol Disposable Hand Sanitizer from the Company has successfully obtained Natural Product Number (NPN) license from Health Canada and the first order of 53,280 bottles have been shipped this week.